Background Mexico has one of the highest prevalence rates of obesity worldwide. New
pharmacological strategies that focus on people with class III obesity are required. Metformin …

The dose‑dependent pharmacological response to dapagliflozin in patients with type 2
diabetes mellitus (T2DM) with regard to weight loss remain unknown. The aim of the present …

Objective The cardio‐renal benefits of sodium glucose‐like transporter 2 inhibitor (SGLT2i)
therapies have been demonstrated in patients with and without type 2 diabetes. However …

Context: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor,
reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing …

Aims Studies on factors affecting weight loss effect after start of dapagliflozin in type 2
diabetes mellitus (T2DM) patients are few. The aim of this study was to identify if there were …

What is known and objectives Dapagliflozin was the first oral treatment approved in type 1
diabetes mellitus (T1DM) patients, simultaneously improving body weight. However, the time …

Aims To explore the effects of dual therapy with dapagliflozin and exenatide on body weight,
body composition, glycaemic variables and systolic blood pressure (SBP) in obese adults …

Aims Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual
therapy with these agents reduces body weight, adipose tissue volume, glycaemia and …

Background: Weight reduction and glycemic control are key goals during Type 2 diabetes
management. However, there are few country-specific, real-world data on cotransporter 2 …

Introduction The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-
like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and …